Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Kezhong Chen, M.D.

Lixin Zhou, M.D.

Jun Wang, M.D.

Fan Yang, M.D.

Xuening Yang, M.D.

Wenzhao Zhong, M.D.

Yilong Wu, M.D.

Feng Yin, M.D.

Lin Xu, M.D.

Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.

Studies have shown the feasibility of detecting mutation status by blood and urine circulating tumor DNA (ctDNA)in non-small cell lung cancer (NSCLC) patients. However, no prospective has been conducted for usage of ctDNA in postoperative surveillance of NSCLC patients.

We plan to compare tumor makers and radiographic approaches with blood and urine ctDNA in surveillance to assess the lead time of postoperative tumor relapse in stage ⅢA NSCLC patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.

Fresh tumor tissue, urine samples and blood samples were collected from each patient.

Time:Preoperative, 3 days and 3、6、12、18、24、30、36 months after surgery.

Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients

A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Stage ⅢA Non-small-cell Lung Cancer Patients

San Valley Biotechnology Incorporated

Peking University People's Hospital

Chief，Thoracic Surgery Service

Blood samples for ctDNA and biomarkers analysis are collected at before chemotherapy and at a series of scheduled time-points after chemotherapy , with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.

Blood samples for ctDNA and biomarkers analysis are collected at before radiotherapy and at a series of scheduled time-points after radiotherapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.

Blood samples for ctDNA and biomarkers analysis are collected at before targeted therapy and at a series of scheduled time-points after targeted therapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.

Yan Zhang, M.D.

Yanhong Shang

Wenbin Shen

Zhenlin Gao

Xiaozhen Wang

Yuquan Ma

Dingzhi Huang, M.D.

Jun Chen, M.D.

Conduct a prospective study in multicenter to confirm the value of circulating tumor DNA in longitudinal monitoring of stage III-IV lung cancer patients.

The study consists of two phases, the first stage is the exploratory stage of blood collection point which is the appropriate effective time after chemotherapy, radiotherapy, targeted therapy. The second phase, which is the expansion of the first phase, is to determine the precise leading time of ctDNA relative to tumor biomarkers or image evaluation in determining the efficacy of advanced NSCLC cancer therapy. Both stages were divided into three subgroups: the chemotherapy group, the radiotherapy group, and the targeted therapy group.

Fresh tumor tissue and blood samples were collected from each patient. Histological specimens (fresh or paraffin blocks) of all enrolled patients before treatment need to be obtained, and according to different adjuvant therapy, blood samples were collected at a series of specific scheduled time-points

Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients

A Prospective Multicenter Study of Longitudinal Monitoring in Treated Stage III-IV Lung Cancer Patients by Circulating Tumor DNA

To explore the appropriate chemo/ radio/ target effective time (CET/RET/TET) through measurement and monitoring of ctDNA after anti-cancer therapies in advanced NSCLC.

To investigate the precise leading time for ctDNA compared to conventional biomarker or image evaluation in detecting disease recurrence after radiotherapy, chemotherapy, or targeted therapy respectively.

To assess the accuracy of ctDNA when imaging undetectable or difficult to assess

Compared to conventional image evaluation, to determine the consistency of ctDNA in treatment response of measurable lesion after radiotherapy, chemotherapy, or targeted therapy respectively

To explore the consistency for ctDNA in determining the efficacy of advanced NSCLC compared to tumor markers after radiotherapy, chemotherapy, or targeted therapy respectively

Study title	NCT ID	Conditions	Eligibility	Organization
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients	NCT02696525	Carcinoma Non-small-cell ... Lung Neoplasms	18 Years - 80 Years	Peking University People's Hospital
Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients	NCT03664843	Carcinoma Non-small Cell ... Lung Neoplasm	18 Years - 80 Years	First Hospital of Shijiazhuang City
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients	NCT02696525	Carcinoma Non-small-cell ... Lung Neoplasms	18 Years - 80 Years	Peking University People's Hospital
Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients	NCT03664843	Carcinoma Non-small Cell ... Lung Neoplasm	18 Years - 80 Years	First Hospital of Shijiazhuang City

Spots Global Cancer Trial Database for lead time

Every month we try and update this database with for lead time cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for lead time

Every month we try and update this database with for lead time cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for lead time cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.